个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

CT-guided Percutaneous Microwave Ablation Combined with Local Radiotherapy or Chemotherapy of Malignant Pulmonary Tumors

| 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Xu Rongde[1] * ; Chen Jingjing[2] * ; Chen Daohua[3] * ; Zhang Xiaobo[4] ; Cui Wei[1] ; Deng Yi[5,6] ; Sun Danxiong[5] ; Yuan Bing[5,*1,*2] ; Li Jing[5,2,*1,*2] ;
机构： [1]Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. Guangzhou, Guangdong, 510080 China [2]Department of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080 China [3]The Second School of Clinical Medicine, Southern Medical University, Guangzhou, Guangdong, 510080 China [4]School of Automation, Guangdong University of Technology, Guangzhou, Guangdong 510006 China [5]Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000 China [6]Medical School, Kunming University of Science and Technology, Kunming, Yunnan, 650000 China
出处：
DOI： 10.2174/0118744710261655231214105406
ISSN：

关键词： CT microwave ablation radiotherapy chemotherapy malignant pulmonary tumors

摘要：
The study aimed to investigate the clinical efficacy of CT-guided microwave ablation (MWA) combined with 125I seed implantation or bronchial arterial infusion (BAI) chemotherapy in the treatment of malignant pulmonary tumors.A total of 56 patients who underwent MWA, MWA combined with 125I particle implantation, or MWA combined with BAI chemotherapy for advanced lung cancer or metastatic lung cancer from January 2015 to June 2021 in Guangdong Provincial People's Hospital were enrolled. Among them, 21 patients were treated with MWA (MWA), 18 with MWA combined with 125I seed implantation (MWA+125I), and 17 with MWA combined with BAI chemotherapy (MWA+BAI). The short-term outcomes, complications, Eastern Cooperative Oncology Group (ECOG) performance score (Zubrod-ECOG-WHO, ZPS), survival, and factors related to survival were compared between the three groups.The response rate of the MWA group (9.52%) was significantly lower than that of the MWA+125I group (50.00%) and MWA+BAI chemotherapy group (47.06%), and the differences were statistically significant (p < 0.05). The incidence of complications in the MWA, MWA+125I, and MWA+BAI chemotherapy groups was 47.62%, 55.56%, and 52.94%, respectively, with no significant difference (p > 0.05). Three months after the treatment, the ZPS of the MWA+125I and MWA+BAI chemotherapy groups was significantly lower than before treatment and significantly lower than that of the MWA group in the same period; the differences were statistically significant (p < 0.05). The median survival time of the MWA+125I group was 18 (9.983, 26.017) months and that of the MWA+BAI chemotherapy group was 21 (0.465, 41.535) months, both of which were higher than that of the MWA group [11 (6.686, 15.314) months]; the differences were statistically significant (p < 0.05). Cox regression analysis was performed on the factors related to survival and revealed treatment mode as a protective factor [HR = 0.433, 95% CI = (0.191, 0.984), p = 0.046]. Other factors, such as gender, age, and tumor size, did not independently affect survival.CT-guided MWA combined with 125I seed implantation and MWA combined with BAI chemotherapy are safe and effective for the treatment of advanced lung cancer and metastatic lung cancer, and can control tumor progression and prolong survival time.Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

基金：
This study has been supported by the Major Science and Technology Special Plan of Biological Medicine of Yunnan Province (No. 202002AA100075).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2024]版：
无
最新[2023]版：
大类 | 4 区 医学
小类 | 4 区 药学 4 区 核医学
JCR分区：
出版当年[2023]版：
Q3 PHARMACOLOGY & PHARMACY Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
最新[2023]版：
Q3 PHARMACOLOGY & PHARMACY Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING

影响因子： 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2022版]

第一作者：
第一作者机构： [1]Department of Interventional Radiology, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences. Guangzhou, Guangdong, 510080 China
共同第一作者：
通讯作者：
通讯机构： [2]Department of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080 China [5]Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000 China [*1]Department of Pulmonary and Critical Care Medicine, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, 510080 China [*2]Department of Pulmonary and Critical Care Medicine, The First People's Hospital of Yunnan Province. The Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan, 650000 China
推荐引用方式(GB/T 7714)：
Xu Rongde,Chen Jingjing,Chen Daohua,et al.CT-guided Percutaneous Microwave Ablation Combined with Local Radiotherapy or Chemotherapy of Malignant Pulmonary Tumors[J].CURRENT RADIOPHARMACEUTICALS.2024,17(2):184-199.doi:10.2174/0118744710261655231214105406.
APA：
Xu Rongde,Chen Jingjing,Chen Daohua,Zhang Xiaobo,Cui Wei...&Li Jing.(2024).CT-guided Percutaneous Microwave Ablation Combined with Local Radiotherapy or Chemotherapy of Malignant Pulmonary Tumors.CURRENT RADIOPHARMACEUTICALS,17,(2)
MLA：
Xu Rongde,et al."CT-guided Percutaneous Microwave Ablation Combined with Local Radiotherapy or Chemotherapy of Malignant Pulmonary Tumors".CURRENT RADIOPHARMACEUTICALS 17..2(2024):184-199

相关文献

[1]Comparison of the efficacy and safety of ultrasound-guided radiofrequency ablation and microwave ablation for the treatment of unifocal papillary thyroid microcarcinoma: a retrospective study [2]超声引导下微波消融与传统甲状腺手术治疗甲状腺良性肿瘤的临床效果 [3]腹腔镜超声引导下微波消融术在结直肠癌肝转移中的应用 [4]Recent advances in ferroptosis and therapeutic strategies for glioblastoma [5]微波消融术在肺癌治疗中的研究进展 [6]Radical esophagectomy for stage II and III thoracic esophageal squamous cell carcinoma followed by adjuvant radiotherapy with or without chemotherapy: Which is more beneficial? [7]Para-aortic lymph node metastasis in lower Thoracic Esophageal Squamous Cell Carcinoma after Radical Esophagectomy: a CT-based atlas and its clinical implications for Adjuvant Radiotherapy. [8]The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. [9]定量检测放、化疗前后大肠癌患者端粒酶活性的临床价值 [10]A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study.

资源点击量：82482 今日访问量：0 总访问量：681 更新日期：2025-01-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 云南省第一人民医院 技术支持：重庆聚合科技有限公司 地址：云南省昆明市西山区金碧路157号